ライフサイエンスコーパス: blood stem cell

1 l transplantation currently using peripheral blood stem cells.

2 iability without effect on normal peripheral blood stem cells.

3 354 after the transplantation of peripheral-blood stem cells.

4 esis for collection of autologous peripheral blood stem cells.

5 owed by infusion of unmanipulated peripheral blood stem cells.

6 e engraftment of CD34(+) selected peripheral blood stem cells.

7 applications for IL-17-mobilized peripheral blood stem cells.

8 elated cord blood, and allogeneic peripheral blood stem cells.

9 tation of ex vivo T-cell-depleted peripheral blood stem cells.

10 ansplants, supported by mobilized peripheral-blood stem cells.

11 etic growth factors or autologous peripheral blood stem cells.

12 undertaken using G-CSF mobilized peripheral blood stem cells.

13 rted in transplant patients who receive cord blood stem cells.

14 ine signaling can instruct lineage choice in blood stem cells.

15 lso required for the formation of definitive blood stem cells.

16 filgrastim to mobilize autologous peripheral-blood stem cells.

17 increased the self-renewal of hematopoietic (blood) stem cells.

18 nmanipulated filgrastim mobilized peripheral blood stem cells (5.5-31.7 x 10(6) cells/kg) from human

19 RIC peripheral blood stem cell allo-HSCT is prospectively feasible for

20 actor (G-CSF) for mobilization of allogeneic-blood stem cells (AlloBSC) has yet to be determined.

21 ine, followed by an infusion of a peripheral-blood stem-cell allograft from an HLA-identical sibling

22 ) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation.

23 successive genetic and epigenetic events in blood stem cells also involves competition and selection

24 teen patients received allogeneic peripheral blood stem cells and 1 received bone marrow after chemot

25 sults in successful collection of peripheral blood stem cells and allows flow rates comparable to tho

26 d 10/10 matched grafts or between peripheral blood stem cells and bone marrow.

27 ion immune reconstitution between peripheral blood stem cells and bone marrow.

28 and monocytes mirrors TL of CD34+ peripheral blood stem cells and progenitor cells extremely well (r=

29 ated to TL in CD34+ hematopoietic peripheral blood stem cells and progenitor cells obtained from the

30 ifference was identical for CD34+ peripheral blood stem cells and progenitor cells, monocytes, granul

31 blood cell populations, including peripheral blood stem cells and progenitor cells.

32 ng factor (G-CSF) mobilization of peripheral blood stem cells and retrovirus transduction using hemat

33 e mesoderm, and contains precursors of adult blood stem cells and the major vessels.

34 Mutant fish engraft muscle, blood stem cells and various cancers.

35 cant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unr

36 of several tissues, is a master regulator of blood stem cells, and plays a role in leukemia.

37 Most (92%) received blood stem cells, and the remainder received bone marrow

38 unrelated donor, matched-sibling peripheral blood stem cells, and unrelated cord blood.

39 Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of

40 Mobilized peripheral blood stem cells are increasingly used for the reconstit

41 lony-stimulating factor-mobilized peripheral blood stem cells are widely used to reconstitute hematop

42 hed frequently from intermittently activated blood stem cells, are short-lived in vivo and may contai

43 ous marrow rescue with or without peripheral-blood stem-cell augmentation to determine the toxicity o

44 teristic of the malignant differentiation of blood stem cells based on studies of alterations that af

45 otential of human bone marrow and peripheral blood stem cells, blood vessels in sex-mismatched transp

46 of evaluable related bone marrow/peripheral blood stem cells (BM/PBSCs), unrelated BM/PBSCs, and unr

47 colony-stimulating factor (G-CSF)-mobilized blood stem cell (BSC) harvests from 104 healthy donors w

48 imulating factor (G-CSF) mobilize peripheral blood stem cells by different mechanisms.

49 d X-CGD patient-mobilized CD34(+) peripheral blood stem cells (CD34(+)PBSCs) with lentivector-gp91(ph

50 ater showed that transduced CD34+ peripheral blood stem cells (CD34+ PBSCs) from this trial transplan

51 t not with donor age, graft type (marrow vs. blood stem cells), CD34 cell dose, conditioning (with vs

52 ge colony-stimulating factor with peripheral blood stem cell collection, and etoposide-dexamethasone-

53 Peripheral-blood stem-cell collection was performed after the secon

54 eatment, with adequate autologous peripheral blood stem-cell collection, and without persistent iatro

55 Analysis of peripheral-blood stem-cell collections by molecular techniques for

56 f the clonogenic cells from human peripheral blood stem cell concentrates were also transducible by A

57 Three peripheral blood stem cell concentrates were collected from 3 macaq

58 ntigen (HLA)-matched related (MR) peripheral blood stem cells conferred protection against early IA c

59 g factor (G-CSF)-mobilized, CD34+ peripheral blood stem cells derived from a patient with the severe

60 Blood stem cells develop at successive sites in the vert

61 Donor Program (NMDP) in promoting unrelated blood stem-cell donation are addressed.

62 lony-stimulating factor-mobilized peripheral blood stem cell donor grafts and successful treatment of

63 cell dose, type of transplant (marrow versus blood stem cells), donor age, or patient age.

64 surface protein expression for selection of blood stem cell donors.

65 reached on safety considerations for healthy blood stem cell donors.

66 In this pilot study, donor peripheral blood stem cell (DPBSC) infusions were performed in thre

67 Starting with a well-characterized blood stem cell enhancer from the SCL gene, we have deve

68 It has been generally held that mobilized blood stem cells express CD34.However, it has also been

69 sed as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell trans

70 essary to definitively establish the role of blood stem cells for allogeneic transplantation, especia

71 ine the feasibility of collecting peripheral blood stem cells for future use.

72 w regulates vascular remodelling, stimulates blood stem cell formation, and has a role in the patholo

73 Peripheral blood stem cells from 2 rhesus monkeys were collected, C

74 lantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates

75 Unmanipulated bone marrow or peripheral blood stem cells from HLA-matched related-donors or HLA-

76 ning regimens using unmanipulated peripheral blood stem cells from human leukocyte antigen (HLA)-comp

77 Forty-two adult recipients of allogeneic blood stem cells from human leukocyte antigen-matched re

78 arrow cells or cytokine-mobilized peripheral blood stem cells from leukocyte antigen-matched animals

79 splanted each year worldwide using marrow or blood stem cells from unrelated volunteers.

80 ell biology and a promising method for human blood stem cell gene therapy.

81 nt information about the basic mechanisms of blood stem cell generation, expansion, and migration.

82 Haematopoiesis is the process whereby blood stem cells give rise to at least fourteen function

83 mor cells from the bone marrow or peripheral blood stem cell graft without causing stem cell damage t

84 CD34+33- cell quantity of the blood stem-cell graft appears to be a more reliable pred

85 lony-stimulating factor-mobilized peripheral blood stem cell grafts (naive and memory T-cell subsets,

86 Allogeneic peripheral blood stem cell grafts contain about 10 times more T and

87 Because unmodified blood stem cell grafts contain one log more T lymphocyte

88 quantity of hematopoietic progenitors in the blood stem cell grafts from filgrastim-stimulated donors

89 eas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4

90 HLA-matched donor bone marrow or peripheral blood stem cell grafts to reconstitute haematopoiesis an

91 Autologous peripheral blood stem cell grafts were CD34+ selected; the particip

92 lowed by reinfusion of autologous peripheral blood stem cells; group E).

93 ecipients of plerixafor mobilized peripheral blood stem cells had a significantly higher incidence of

94 for 7 days and autologous CD34(+) peripheral blood stem cells harvested by leukapheresis.

95 and more cost-effective, than typical BM or blood stem cell harvesting.

96 n bone marrow and mobilized human peripheral blood stem cell harvests.

97 rd blood banking and transplantation of cord blood stem cells has advanced rapidly over the initial 2

98 ugh the use of cytokine-mobilized peripheral blood stem cells has gained a significant momentum in cl

99 Human cord blood stem cells (hCBSCs) have been reported to generate

100 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplantation (URD-

101 lant conditioning, and the use of peripheral blood stem cells in hematopoietic cell transplantation (

102 and erythroid differentiation of peripheral blood stem cells in liquid culture.

103 in swine, by using high doses of peripheral blood stem cells in the absence of WBI.

104 nt recipients for a long time, recipients of blood stem cells may be less immunocompromised than reci

105 condary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, w

106 tation of unmanipulated filgrastim-mobilized blood stem cells may result in a relatively high inciden

107 uction therapy and then underwent peripheral blood stem-cell mobilisation and harvesting if applicabl

108 filed in murine and rhesus monkey peripheral blood stem cell mobilization and transplantation models.

109 enhancing its myeloprotective or peripheral blood stem cell mobilization properties, which can be us

110 y transplant studies in mice, and peripheral blood stem cells mobilized by AMD3100 and granulocyte co

111 lative transplantation with CD34+ peripheral-blood stem cells, mobilized by granulocyte colony-stimul

112 T cells from CD34-enriched human peripheral blood stem cells modified with a lentiviral vector desig

113 promote human B cell development in the cord blood stem cell/MS-5 culture, we made the unexpected fin

114 bited development of CD19+ cells in the cord blood stem cell/MS-5 culture.

115 -lineage cells purified from xenogeneic cord blood stem cell/MS-5 murine stromal cell cultures, to fu

116 We used a xenogeneic human cord blood stem cell/murine stromal cell culture to study the

117 rphologically normal BM (n = 22), peripheral blood stem cells (n = 10) from patients with cancers oth

118 Patients received either peripheral-blood stem cells (n = 13) or bone marrow (n = 8).

119 The graft consisted of bone marrow (n = 86), blood stem cells (n = 25), or both (n = 11).

120 lony stimulating factor mobilized peripheral blood stem cells (n = 4), and a VCA transplant from the

121 (n=8) or ex vivo T-cell-depleted peripheral blood stem cells (n=4) for chemorefractory hematologic m

122 d an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched rel

123 bition on sale did not encompass "peripheral blood stem cells" obtained through apheresis.

124 ce of megakaryocytes derived from peripheral blood stem cells of GT patients.

125 rapeutic regimens with autologous peripheral blood stem cell or allogeneic bone marrow rescue are rig

126 Support with peripheral blood stem cells or bone marrow and with granulocyte col

127 Autologous peripheral-blood stem cells or bone marrow were infused on day 0.

128 ndomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratifi

129 chemotherapy alone (P = .006), marrow versus blood stem cell (P = .01), serum ALT greater than 50 IU/

130 study was conducted of autologous peripheral blood stem cell (PBSC) collection in 27, followed by tra

131 ociated with filgrastim mobilized peripheral blood stem cell (PBSC) collections in unrelated voluntee

132 by 2726 bone marrow (BM) and 6768 peripheral blood stem cell (PBSC) donors who underwent collection o

133 We studied whether peripheral blood stem cell (PBSC) graft iNKT-cell dose affects on t

134 Unfractionated peripheral blood stem cell (PBSC) grafts contain measurable quantit

135 etion of TN from human allogeneic peripheral blood stem cell (PBSC) grafts would reduce GVHD and prov

136 Peripheral-blood stem cell (PBSC) harvest and surgical resection of

137 elotoxicity can be ameliorated by peripheral blood stem cell (PBSC) infusion.

138 Peripheral blood stem cell (PBSC) infusions are associated with com

139 ate the safety and feasibility of peripheral blood stem cell (PBSC) mobilization in 8 SCT subjects an

140 A reliable estimate of peripheral blood stem cell (PBSC) mobilization response to granuloc

141 e effects of various schedules of peripheral blood stem cell (PBSC) reinfusion, granulocyte colony-st

142 High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the tre

143 b), combined with doxorubicin and peripheral blood stem cell (PBSC) support in advanced medullary thy

144 host-reactive donor T cells from peripheral blood stem cell (PBSC) transplant allografts ex vivo usi

145 patients receiving an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA-identical

146 Peripheral blood stem cell (PBSC) transplantation is successful in

147 Peripheral blood stem cell (PBSC) transplantation may provide a str

148 myeloablative versus conventional peripheral blood stem cell (PBSC) transplants from HLA-matched sibl

149 tropenic recipients of autologous peripheral blood stem cell (PBSC) transplants.

150 Autologous peripheral blood stem cell (PBSC)-supported high-dose melphalan is

151 Currently, peripheral blood stem cells (PBSC) are infused after myeloablative

152 which is widely used to mobilize peripheral blood stem cells (PBSC) from normal donors, has led to t

153 Recipients of peripheral blood stem cells (PBSC) had faster recovery and fewer pl

154 Peripheral blood stem cells (PBSC) have become the preferred source

155 Peripheral-blood stem cells (PBSC) may be used as an alternative to

156 h autologous SCT, currently using peripheral blood stem cells (PBSC) mobilized by chemotherapy and re

157 Peripheral blood stem cells (PBSC) obtained from granulocyte-colony

158 Autologous transplantation with peripheral blood stem cells (PBSC) results in faster haematopoietic

159 Human peripheral blood stem cells (PBSC) were obtained by leukapheresis f

160 f 18 at level II received BM plus peripheral-blood stem cells (PBSC).

161 periences of 69 (38 marrow and 31 peripheral blood stem cell [PBSC]) donors participating in a random

162 rrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients.

163 in the study donated either BM or peripheral blood stem cells (PBSCs) according to center policy.

164 Mobilized peripheral blood stem cells (PBSCs) are widely used for transplanta

165 atelet development in which human peripheral blood stem cells (PBSCs) differentiate along megakaryocy

166 Sixty-five patients received peripheral blood stem cells (PBSCs) from HLA-identical siblings, an

167 Two patients received peripheral blood stem cells (PBSCs) from matched-related donors, 2

168 Peripheral blood stem cells (PBSCs) have been widely adopted as a s

169 Although peripheral blood stem cells (PBSCs) have replaced bone marrow (BM)

170 he majority of the most primitive peripheral blood stem cells (PBSCs) in PNH appear to be of normal p

171 lating factor (G-CSF) to mobilize peripheral blood stem cells (PBSCs) is increasing.

172 chemotherapy (HDC) supported with peripheral-blood stem cells (PBSCs) is related to the dose of CD34(

173 on with syngeneic plus allogeneic peripheral blood stem cells (PBSCs) is sufficient to interrupt auto

174 se chemotherapy, patients who had peripheral-blood stem cells (PBSCs) mobilized with filgrastim or th

175 s infusions of autologous CD34(+) peripheral blood stem cells (PBSCs) that had been transduced ex viv

176 , 609 recipients of HLA-identical peripheral-blood stem cells (PBSCs), and 675 recipients of unrelate

177 lated donor transplant from BM or peripheral blood stem cells (PBSCs).

178 onuclear cells (PBMCs), and CD34+ peripheral blood stem cells (PBSCs).

179 preferred source of the graft was peripheral blood stem cells (PBSCs).

180 by using bone marrow (n = 93) or peripheral blood stem cells (PBSCs; n = 49).

181 rce of stem cells (bone marrow vs peripheral blood stem cells [PBSCs]), age, sex, graft-versus-host d

182 r frequency in pre-HCT marrow and peripheral-blood stem cells predicted for primitive progenitor reco

183 h Fanconi anemia is collection of peripheral blood stem cells prior to the development of severe panc

184 identical related donors, and umbilical cord blood stem cell products are frequently used when a well

185 Cytokine-mobilized peripheral blood stem cell products are increasingly used for hemat

186 e DA roof, a ventral Bmp4 signal induces the blood stem cell program in the DA floor.

187 wine using a high-dose allogeneic peripheral blood stem cell protocol.

188 ma(null) mice engrafted with human mobilized blood stem cells provide a new in vivo long-lived model

189 lony-stimulating factor-mobilized autologous blood stem cells provided hematopoietic rescue.

190 ransplantation in 9 marrow recipients and no blood stem cell recipients (P =.008).

191 ce of chronic GVHD in previously reported 37 blood stem cell recipients and 37 computer-matched histo

192 2 years posttransplant among the peripheral blood stem cell recipients compared with the marrow reci

193 Blood stem cell recipients did not have higher antibody

194 In conclusion, blood stem cell recipients have higher lymphocyte-subset

195 f most lymphocyte subsets were higher in the blood stem cell recipients.

196 s and transfusion requirements in autologous blood stem-cell recipients.

197 d transcriptional enhancer elements with the blood stem cell regulator TAL1/SCL.

198 ype-specific binding and (iii) knock-down of blood stem cell regulators in mast cells reveals mast ce

199 zed protein-protein interactions between key blood stem cell regulators.

200 py with autologous bone marrow or peripheral blood stem cell rescue is one of the most aggressive tre

201 tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation, and sugges

202 tepa and etoposide and autologous peripheral blood stem-cell rescue before craniospinal irradiation.

203 cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation to the prim

204 cycles of high-dose therapy with peripheral blood stem-cell rescue, local radiotherapy, and 13-cis-r

205 e cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients completed two cycle

206 cycles of high-dose therapy with peripheral blood stem-cell rescue.

207 mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated mice.

208 ustine (RR = 2.3) and with use of peripheral blood stem cells (RR = 2.4).

209 The prognostic importance of peripheral blood stem cell source in critically ill HSCT recipients

210 silencing to non-canonical functions during blood stem cell specification.

211 erved, pretransplant bone marrow, peripheral blood stem cell specimens, obtained at the time of harve

212 dose melphalan-based therapy with peripheral blood stem cell support and, hence, should not constitut

213 or growth factor mobilization and peripheral blood stem cell support compared with bone marrow transp

214 herapy with either bone marrow or peripheral blood stem cell support.

215 strated dramatic expansion of umbilical cord blood stem cells that promote rapid engraftment while ma

216 onors, 4) increasing the yield of peripheral blood stem cells through synergy with other hematopoieti

217 Sufficient peripheral blood stem cells to support two HDT cycles (CD34 > 5 x 1

218 tubated patients, those receiving peripheral blood stem cell transplant (PBSCT) had significantly bet

219 ents who had received a marrow or peripheral blood stem cell transplant from an HLA-identical sibling

220 nt Enterococcus faecalis infection in a cord blood stem cell transplant recipient previously treated

221 cutive series of 116 evaluable HLA-identical blood stem cell transplant recipients.

222 ity and achieve engraftment of an allogeneic blood stem cell transplant, allowing a graft-versus-mali

223 ve the utility and convenience of peripheral blood stem cell transplant.

224 hal case of pneumonia following a peripheral blood stem cell transplant.

225 lony stimulating-factor-mobilized peripheral-blood stem-cell transplant from his HLA-identical brothe

226 med a nonmyeloablative allogeneic peripheral-blood stem-cell transplant in this patient to exploit a

227 chronic GVHD was significantly higher after blood stem cell transplantation (1-year probability [95%

228 Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) is a common

229 herapy with or without autologous peripheral blood stem cell transplantation (APBSCT).

230 Blood stem cell transplantation (BSCT) results in rapid

231 emotherapy followed by autologous peripheral blood stem cell transplantation (HDM/SCT) can produce he

232 halan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been deve

233 tution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id i

234 High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associa

235 oved response rates observed with peripheral blood stem cell transplantation (PBSCT) in patients with

236 Allogeneic peripheral blood stem cell transplantation (PBSCT) is increasingly

237 Peripheral blood stem cell transplantation (PBSCT) is the most comm

238 icenter phase III trial comparing peripheral blood stem cell transplantation (PBSCT) to bone marrow t

239 is better in patients undergoing peripheral blood stem cell transplantation (PBSCT), but the selecti

240 is of patients with AL undergoing peripheral blood stem cell transplantation (PBSCT).

241 rgoing high-dose chemotherapy and peripheral blood stem cell transplantation (PSCT).

242 High-dose melphalan with autologous blood stem cell transplantation (SCT) can reverse the di

243 tion to hospital discharge was 23 days after blood stem cell transplantation and 28 days after bone m

244 y JC papovavirus after autologous peripheral blood stem cell transplantation and a case each of cytom

245 ute to inferior platelet recovery after cord blood stem cell transplantation and may underlie ineffic

246 roid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in

247 ith autologous and allogeneic bone marrow or blood stem cell transplantation appear to induce a prolo

248 d recovery of hematopoiesis after allogeneic blood stem cell transplantation has been attributed to t

249 0(4) T cells/kg) nonmyeloablative peripheral blood stem cell transplantation in children and young ad

250 Peripheral blood stem cell transplantation is being used more frequ

251 NCA (131)I-MIBG with autologous peripheral blood stem cell transplantation is feasible at 666 MBq/k

252 dministration of filgrastim after allogeneic blood stem cell transplantation shortens the time to neu

253 on the topic of cord blood banking and cord blood stem cell transplantation was conducted for this t

254 ymph node irradiation (TMLI), for peripheral blood stem cell transplantation, in patients with advanc

255 Two days before allogeneic peripheral blood stem cell transplantation, miniature swine were co

256 chronic GVHD after HLA-identical allogeneic blood stem cell transplantation, that clinical factors m

257 (2) intravenously) and autologous peripheral blood stem cell transplantation, with marked improvement

258 ions of allogeneic bone marrow or peripheral blood stem cell transplantation.

259 er allogeneic marrow or filgrastim-mobilized blood stem cell transplantation.

260 py, whole-brain radiotherapy, and peripheral blood stem cell transplantation.

261 risk factors for acute GVHD after allogeneic blood stem cell transplantation.

262 f graft-versus-host disease after peripheral blood stem cell transplantation.

263 ent infection in encephalitis following cord blood stem cell transplantation.

264 RIC unrelated adult donor or umbilical cord blood stem cell transplantation.

265 tion (ABMT) (n = 46) or mobilized peripheral-blood stem-cell transplantation (PBSCT) (n = 47).

266 high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplantation (PBSCT) at Indiana Unive

267 disease (GVHD) is increased after peripheral-blood stem-cell transplantation (PBSCT) when compared wi

268 ho underwent autologous marrow or peripheral-blood stem-cell transplantation at our institution betwe

269 owed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients with follic

270 nic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical si

271 c granulomatous disease underwent peripheral-blood stem-cell transplantation from an HLA-identical si

272 ensive intravenous melphalan with autologous blood stem-cell transplantation improves the nephrotic s

273 ensive intravenous melphalan with autologous blood stem-cell transplantation induces remission of the

274 oplatin and etoposide followed by peripheral-blood stem-cell transplantation or autologous bone marro

275 sus-host disease after allogeneic peripheral blood stem-cell transplantation who had severe refractor

276 who would have been eligible for peripheral-blood stem-cell transplantation.

277 ns of nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

278 ompared results of 288 HLA-identical sibling blood stem cell transplantations with results of 536 HLA

279 Recipients of blood stem cell transplants had more rapid recovery of n

280 eukemia-free survival rates were higher with blood stem cell transplants in patients with advanced le

281 ata from 663 unrelated marrow and peripheral blood stem cell transplants performed from 1995 to 2007

282 adult recipients of HLA-identical allogeneic blood stem cell transplants.

283 or between patients who received peripheral-blood stem-cell transplants and unpurged autologous bone

284 bolites in patients who underwent peripheral-blood stem-cell transplants.

285 metabolites in patients following peripheral-blood stem-cell transplants; (2) allow consideration of

286 ts the concept that the mobilized peripheral blood stem cells used in clinical transplantation functi

287 in, CD34-selected, c-kit(+) human peripheral blood stem cells using a c-kit-targeted adenovirus vecto

288 mized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donor

289 Peripheral blood stem cells were associated with a nonsignificant i

290 Peripheral blood stem cells were collected from responding patients

291 Sufficient numbers of peripheral-blood stem cells were collected in all but one patient.

292 CD34+ cord blood stem cells were cultured on the MS-5 murine stroma

293 Unselected peripheral blood stem cells were harvested with cyclophosphamide (2

294 Peripheral blood stem cells were mobilized with cyclophosphamide (2

295 Peripheral blood stem cells were mobilized with cyclophosphamide an

296 er induction therapy and surgery, peripheral-blood stem cells were mobilized with three cycles of hig

297 f ATG used, and CD34-selection of peripheral blood stem cells were not found to be significantly asso

298 whereas HLA-matched sibling donor peripheral blood stem cells were significantly worse (25%, 95% CI 2

299 cells, developed in vitro from CD34(+) cord blood stem cells, were experimentally infected with the

300 ies were randomized to receive marrow versus blood stem cells, which contain approximately 10 times m